Section Chief: Joseph D. Locker, MD, PhD
The Molecular Oncology Laboratory provides comprehensive nucleic acid-based tests for the diagnosis and management of neoplasia. Specimens are most often submitted for gene studies of leukemia and lymphoma and molecular markers of residual neoplastic disease.
Select this link for information regarding specific tests performed by the Molecular Oncology Laboratory, including a full list of tests, consultation contacts, and details for specimen preparation and delivery.
See below for more general information about the techniques used by the Molecular Oncology Laboratory.
Southern blot and quantitative dot blot hybridization systems and PCR-based amplification systems provide a level of sensitivity unequaled by routine histopathological analysis, flow cytometry, or karyotypic analysis. For example, detection of neoplastic cells constituting as few as 1 % of the cells in a specimen is frequently attainable by Southern blot analysis. Further, one neoplastic cell in a background of 10,000 normal cells routinely can be detected in PCR-based studies.
The value of these sensitive techniques in clinical practice is illustrated in the following settings:
Professional consultation concerning appropriate testing for individual patients is available by contacting Joseph Locker, MD, PhD, at (412) 648-8253 or Jeffery Kant, MD, PhD, at (412) 648-8519.
(For more information about the tests performed by the Molecular Oncology Laboratory, please click here.)
The test(s) is (are) performed under an agreement with Roche Molecular Systems, Inc.